Source: Recovery Trial

Professor Peter Horby, Professor Martin Landray
RECOVERY trial Co-chairs
Nuffield Department of Public Health
Oxford
24th May 2020


Dear Peter and Martin

RECOVERY trial DMC Chairman’s report
In the light of the response by MHRA to my letter, I arranged an urgent re- review by the full committee of the safety and efficacy data that were available by 12.22hrs on the 23rd May, for the 10,680 patients randomised.
The Committee reviewed the external evidence from the non-randomised observational study (Mehra et al. Lancet May 22nd 2020) and the evidence from the RECOVERY trial on the effects of
hydroxychloroquine on mortality among patients admitted to hospital with COVID-19.

We saw no cogent reason to suspend recruitment for safety reasons. In particular, we noted that the hazard ratio for 28-day mortality (our primary outcome) in the current RECOVERY data differs significantly (at 2p=0.01) to the HR of 1.335 from the non-randomised assessment reported by Mehra et al.

Professor Peter Sandercock

The Committee therefore recommends the trial continue recruitment without interruption until the next scheduled meeting of the full Committee on 28th May.

Yours sincerely,

Professor Peter Sandercock, MA, DM, FRCPE, FESO, FWSO
Emeritus Professor of Medical Neurology, Centre for Clinical Brain Sciences
Chairman RECOVERY trial DMC
Cc DMC members, RECOVERY trial office, MHRA



Related:

Health Canada approves continuation of hydroxychloroquine clinical trials, deplores Lancet study that influenced WHO

Share on facebook
Share on twitter
Share on whatsapp
On Trend

Latest Stories

A Judge Stands up to a Hospital: “Step Aside” and Give a Dying Man Ivermectin

The judge’s finest moment may have been when he dashed the most glaring myth about ivermectin—that it is not safe, despite decades of use that shows otherwise. Noting that all drugs have side effects, Judge Fullerton listed ivermectin’s effects from a government website.
“(N)umber one, generally well tolerated; number two, dizziness; number three, pruritus; number four, nausea/diarrhea. These are the side effects for the dosage that’s being asked to be administered,” he said. “The risks of these side effects are so minimal that Mr. Ng’s current situation outweighs that risk by one-hundredfold.”

Read More »

How Dr. Paul Marik Saved a Grandmother & The World (Part 3)

Recently Merck issued a stern warning that seemed written by marketing, Kory says, “as it had no scientific data to support the conclusion,” that ivermectin was suddenly dangerous. Another pharmaceutical company’s CEO privately noted that “People must think Merck knows what they’re talking about because it’s their drug,” but Merck has “tremendous disincentives” to say nice things about the generic pill, as it has already spent hundreds of millions of dollars developing an oral anti-viral COVID-19 treatment, rival to ivermectin, that may be priced at $3,000 a dose.

Read More »

How Dr. Paul Marik Saved a Grandmother & The World (Part 2)

They also restricted the use of essential off-label and generic drugs with blatant disinformation campaigns that reminded Kory of big tobacco’s efforts to hide the dangers of smoking. In effect, the public health authorities eliminated the full toolbox of essential scientific methods and drugs that doctors use every day, including the most effective early, prophylactic, and late-stage treatments for COVID-19, which were developed by frontline doctors, not pharmaceutical companies.

Read More »

How Dr. Paul Marik Saved a Grandmother & The World (Part I)

In the professor’s continual review of “the latest (and best) literature,” he picked up a surprising “data signal” in October from emerging studies in Latin America. ivermectin, a safe, cheap, FDA-approved anti-parasitic drug, was showing remarkable anti-viral and anti-inflammatory activity as a repurposed drug—the most powerful COVID-19 killer known to science. 

Read More »